Nextcure, Inc. · NASDAQ:NXTC
Nextcure — Investor Presentation (December 2024)
20 slides from Nextcure's investor presentation, Dec 5, 2024
Slide 1: Corporate Presentation December 2024
Corporate Presentation NASDAQ: NXTC DECEMBER 2024
Slide 2: Forward-Looking Statement
Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forec
Slide 3: Value-Driven ADC Opportunity
3 Value-Driven ADC Opportunity • IND submitted Q4 2024 • Breast, endometrial and ovarian cancers • FIH expected in Q1 2025 2024-2025 DELIVERABLES SIGNIFICANT OPPORTUNITY • Antibody-drug conjugate targeting B7-H4 • Differentiated linker for improved safety and increased efficacy • Completed GLP tox s
Slide 4: LNCB74: Differentiated B7-H4 ADC Therapeutic
4 LNCB74 LEVERAGING OUR DEEP EXPERTISE IN B7-H4 AND COLLABORATION WITH LCB TO DEVELOP A DIFFERENTIATED THERAPEUTIC Breast CANCER Ovarian CANCER Endometrial CANCER
Slide 5: Focused on a Clinically Validated Target with High Unmet Need
Focused on a Clinically Validated Target with High Unmet Need 5 PROGRAMS TARGET CELLS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES LNCB74 (ADC) B7-H4 Tumor Cells FIH Q1 2025 Co-development with Breast, Ovarian, Endometrial
Slide 6: Differentiated ADC LNCB74 B7-H4 ADC
6 THERAPEUTIC POSITIONING Improved safety and efficacy PATIENT SELECTION STRATEGY CLIA validated IHC biomarker assays NOVEL APPROACH Unique antibody linker strategy Co-development partnership with LCB DEEP EXPERTISE Significant B7-H4 experience LCB’s substantial ADC know-how Differentiated ADC LNCB7
Slide 7: B7-H4 is the Next Target of Interest in Women's Cancer
B7-H4 is the Next Target of Interest in Women’s Cancer 7 In 2nd big deal of the day, GSK inks $1.4B pacy for Hansoh gynecology cancer asset NextCure, LegoChem* join big-league rivals in antibody-drug conjugate race *Currently known as LigaChemBio
Slide 8: Deep Expertise in B7-H4
Deep Expertise in B7-H4 8 • Extensive publications • Expertise in expression • Repertoire of models • Top-tier KOL collaborative network • Validated patient selection assay • Co-development & cost-sharing • Significant success advancing ADCs • Differentiated linker technology
Slide 9: LNCB74 Initiation of Phase 1
LNCB74 Initiation of Phase 1 9 ✓ Potent pre-clinical activity in vitro and in vivo ✓ DRF & GLP tox studies – favorable safety and tolerability profile ✓ Favorable pre-IND feedback from FDA ✓ GMP manufacturing ✓ IND filing • Planning for Ph1 initiation COMPLETED ONGOING
Slide 10: LNCB74 Is an Anti-B7-H4 MMAE ADC
LNCB74 Is an Anti-B7-H4 MMAE ADC Fc Modification Protects immune cells Tumor Selectivity Glucuronidase cleavable linker provides greater selectivity and specificity 10 MMAE DAR 4 Improves safety and control over how the payload is dispersed Antibody Linker Payload STRUCTURAL DIFFERENTIATION
Slide 11: LNCB74 Uses Differentiating Glucuronidase Linker
LNCB74 Uses Differentiating Glucuronidase Linker for Potentially Improved Safety & Efficacy 11 Bloodstream Tissues Cancer Cell Bystander Effect Linker Glucuronidase cleavable Payload Tubulin inhibitor Conjugation Site Specific DAR 4 •Efficient release of toxin •Higher concentration Stable No Toxicit
Slide 12: Key Differentiating Features of Glucuronidase Linkers
Key Differentiating Features of Glucuronidase Linkers 12 Time (Hours) Relative Toxin Concentration per Cancer Cell 100% Val-cit Linker Glucuronidase Linker Control ADC Glucuronidase Linker Val-Cit Linker Site specific attachment to mAb □ Non-specific attachment to mAb Highly stable linkage □ Uns
Slide 13: LNCB74 Shows Potent Anti-Tumor Activity in CDX and PDX Models
13 LNCB74 Shows Potent Anti-Tumor Activity in CDX and PDX Models OVARIAN (OVCAR-3-B7-H4-OE) Days from Treatment Initiation Mean Volume (mm3) +/- SEM TNBC (CTG-0012) Mean Volume (mm3) +/- SEM Days from Treatment Initiation BREAST (ZR-75-1) Days from Treatment Initiation Mean Tumor Volume (mm3) +/- SE
Slide 14: LNCB74 is More Effective than Comparator B7-H4-MMAE
LNCB74 is More Effective than Comparator B7-H4-MMAE 14 0 10 20 30 40 0 500 1000 1500 2000 No Treatment LNCB74 3 mg/kg Comp 3 mg/kg 0 10 20 30 40 0 500 1000 1500 2000 No Treatment Comp 4.5 mg/kg LNCB74 4.5 mg/kg 0 10 20 30 40 0 500 1000 1500 2000 No Treatment LNCB74 6 mg/kg Comp 6mg/kg 30 40 50 60 0
Slide 15: B7-H4 is a Validated ADC Target
B7-H4 is a Validated ADC Target Key Features LNCB74 SGN-B7H4V XMT-1660 HS-20089 AZD8205 DB-1312 / BG-C9074 ADC Design • B7-H4 mAb • B7-H4 mAb • B7-H4 mAb • B7-H4 mAb • B7-H4 mAb • B7-H4 mAb • Glucuronidase cleavable linker • Val-Cit cleavable linker • Protease cleavable linker • Protease cleavable l
Slide 16: GLP Tox and GMP Manufacturing Complete
TOX STUDY GMP MANUFACTURING 16 GLP Tox and GMP Manufacturing Complete Species Cynomolgus Dose Range 4, 7 & 10 mg/kg Q3W, i.v. Evaluation Toxicology profiling, pathology, hematology, immunotoxicology Findings Favorable safety and tolerability profile Master cell bank generated Process development com
Slide 17: LNCB74 Ph1 Monotherapy Study Plans
DOSE ESCALATION DOSE EXPANSION 17 LNCB74 Ph1 Monotherapy Study Plans • 5 dose cohorts • Regimen Q3W • N=65 subjects • 2 dose cohorts • 2 tumor types • N=80 subjects • Pre-treatment & on study biopsies Breast CANCER Ovarian CANCER Endometrial CANCER Readouts: Scans every 6 weeks Endpoints: Safety and
Slide 18: Opportunity to Develop Differentiated B7-H4 ADC Therapeutic
POTENTIAL FOR IMPROVED SAFETY & EFFICACY Opportunity to Develop Differentiated B7-H4 ADC Therapeutic 18 B7-H4 ADC UNMET NEED IN BREAST & GYNECOLOGICAL CANCERS PATIENT SELECTION STRATEGY
Slide 19: Programs Available for Partnering
Programs Available for Partnering 19 PROGRAMS TARGET CELLS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NC410 Combo LAIR-2 Extracellular Matrix NC525 LAIR-1 Leukemia NC605 S15 Osteoclasts NC181 APOE4 Microglia & Neurons Alzheimer’s Disease Osteogenesis Imperfecta Acute Myeloid Leukemia Colorectal (
Slide 20: Anticipated Milestones
20 Anticipated Milestones ✓Completed GLP tox study and GMP manufacturing for Ph 1 trial ✓IND submitted Q4 2024 • FIH expected in Q1 2025 2024-2025 DELIVERABLES SIGNIFICANT OPPORTUNITY • Antibody-drug conjugate targeting B7-H4 • Breast, endometrial and ovarian cancers • Differentiated linker for impr